310 related articles for article (PubMed ID: 7727053)
1. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
Santeusanio F; Compagnucci P
Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
[TBL] [Abstract][Full Text] [Related]
2. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.
Balfour JA; McTavish D
Drugs; 1993 Dec; 46(6):1025-54. PubMed ID: 7510610
[TBL] [Abstract][Full Text] [Related]
3. Acarbose: an alpha-glucosidase inhibitor.
Martin AE; Montgomery PA
Am J Health Syst Pharm; 1996 Oct; 53(19):2277-90; quiz 2336-7. PubMed ID: 8893066
[TBL] [Abstract][Full Text] [Related]
4. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
Toeller M
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():31-5. PubMed ID: 8001625
[TBL] [Abstract][Full Text] [Related]
5. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
Clissold SP; Edwards C
Drugs; 1988 Mar; 35(3):214-43. PubMed ID: 3286212
[TBL] [Abstract][Full Text] [Related]
6. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
7. Acarbose: a review of US clinical experience.
Coniff R; Krol A
Clin Ther; 1997; 19(1):16-26; discussion 2-3. PubMed ID: 9083705
[TBL] [Abstract][Full Text] [Related]
8. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic relationships of Acarbose.
Salvatore T; Giugliano D
Clin Pharmacokinet; 1996 Feb; 30(2):94-106. PubMed ID: 8906894
[TBL] [Abstract][Full Text] [Related]
10. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
11. Effects of beano on the tolerability and pharmacodynamics of acarbose.
Lettieri JT; Dain B
Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with acarbose as first line therapy in NIDDM.
Fölsch UR
Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Hoffmann J; Spengler M
Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with acarbose: results of a Canadian multicentre study.
Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
17. New horizons in diabetes therapy--alpha glucosidase inhibitors.
Jawad F
J Pak Med Assoc; 1994 Mar; 44(3):59-60. PubMed ID: 8040998
[No Abstract] [Full Text] [Related]
18. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Josse RG
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
[TBL] [Abstract][Full Text] [Related]
19. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott LJ; Spencer CM
Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
[TBL] [Abstract][Full Text] [Related]
20. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
